🇺🇸 FDA
Patent

US 10010524

Short acting phenylalkylamine calcium channel blockers and uses thereof

granted A61KA61K31/216A61K31/26

Quick answer

US patent 10010524 (Short acting phenylalkylamine calcium channel blockers and uses thereof) held by Milestone Pharmaceuticals Inc. expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Milestone Pharmaceuticals Inc.
Grant date
Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/216, A61K31/26, A61K31/275, A61K31/277